Sprycel

Report
Dr. Adham Abu Taha
Presented by:
Raya M.Walid Salah
Sprecyl
Introduction
 Mechanism of action
 Pharmacokinetic
 Side effects
 Contraindications
 Major drug-drug interactions

Sprycel
Generic name: Dasatinib
 Brand name: Sprycel
 Company: Bristol-Myers Squibb
 Indication: Philadelphia chromosome
positive chronic myeloid leukemia
 Approval date: October, 2010

Chronic Myeloid Leukemia
It is a form of leukemia characterized by
the increased and unregulated growth of
myeloid cells in the bone marrow and the
accumulation of these cells in the blood.
 Caused by a translocation between
chromosome 9 and chromosome 22, which
produces the kinase BCR-Abl.

Mechanism of Action

Sprycel is a kinase inhibitor that binds to
the ATP site of the active conformation of
BCR-Abl.
Pharmacokinetic
Oral bioavailability: 20%
 Binds extensively to plasma proteins (96%)
 Metabolized in the liver by CYP3A4,
eliminated mainly by the feces.
 Plasma half-life: 3-5 hours.
 Dosage: 100 mg once daily.

Side Effects
Low blood cell count: anemia, neutropenia
and thrombocytopenia.
 Bleeding
 Fluid retention
 Heart problems
 GI problems: nausea, vomiting, diarrhea.
 Tiredness, weakness, fever and fatigue.

Contraindications
Pregnancy
 Breast-feeding
 Patients under 18 years old

Drug Interactions
CYP3A4 inhibitors: Ketoconazole, Ritonavir,
Indinavir, Erythromycin, Clarithromycin.
 CYP3A4 inducers: Dexamethasone,
Phenytoin, Rifampin, Phenobarbital.
 Drugs that reduce stomach acidity.

Thank
You

similar documents